Concepts (138)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 14 | 2021 | 848 | 1.760 |
Why?
|
| Glioblastoma | 9 | 2017 | 285 | 1.260 |
Why?
|
| Glioma | 6 | 2021 | 321 | 1.130 |
Why?
|
| Angiogenesis Inhibitors | 5 | 2012 | 299 | 0.760 |
Why?
|
| Subarachnoid Hemorrhage, Traumatic | 1 | 2012 | 3 | 0.380 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2021 | 1463 | 0.360 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2012 | 1021 | 0.300 |
Why?
|
| ErbB Receptors | 2 | 2011 | 513 | 0.270 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2007 | 159 | 0.250 |
Why?
|
| Drug Therapy | 1 | 2005 | 70 | 0.230 |
Why?
|
| Antibodies, Monoclonal | 5 | 2011 | 1425 | 0.220 |
Why?
|
| Bevacizumab | 6 | 2021 | 275 | 0.200 |
Why?
|
| Dacarbazine | 2 | 2013 | 101 | 0.180 |
Why?
|
| Re-Irradiation | 1 | 2021 | 17 | 0.180 |
Why?
|
| Salvage Therapy | 2 | 2010 | 238 | 0.150 |
Why?
|
| Chemoradiotherapy | 1 | 2021 | 327 | 0.150 |
Why?
|
| Hospitals, Low-Volume | 1 | 2017 | 22 | 0.130 |
Why?
|
| Hospitals, High-Volume | 1 | 2017 | 42 | 0.130 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2007 | 315 | 0.120 |
Why?
|
| Cerebral Cortex | 3 | 1990 | 615 | 0.120 |
Why?
|
| Signal Transduction | 1 | 2006 | 3581 | 0.120 |
Why?
|
| Paraneoplastic Syndromes, Nervous System | 1 | 2015 | 9 | 0.110 |
Why?
|
| Antineoplastic Agents | 3 | 2013 | 2385 | 0.110 |
Why?
|
| Neoplasm Staging | 3 | 2010 | 2042 | 0.110 |
Why?
|
| Survival Analysis | 2 | 2007 | 1540 | 0.110 |
Why?
|
| Humans | 18 | 2021 | 95802 | 0.110 |
Why?
|
| Neurosurgical Procedures | 2 | 2007 | 356 | 0.110 |
Why?
|
| Graft Rejection | 3 | 1990 | 1126 | 0.100 |
Why?
|
| Combined Modality Therapy | 2 | 2007 | 1739 | 0.100 |
Why?
|
| Male | 13 | 2017 | 45686 | 0.100 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2015 | 303 | 0.100 |
Why?
|
| Neurology | 1 | 2014 | 83 | 0.100 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2012 | 18 | 0.090 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2015 | 684 | 0.090 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2012 | 135 | 0.090 |
Why?
|
| Treatment Outcome | 6 | 2011 | 9167 | 0.090 |
Why?
|
| Radiotherapy | 1 | 2013 | 325 | 0.080 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 787 | 0.080 |
Why?
|
| Snake Venoms | 1 | 2010 | 9 | 0.080 |
Why?
|
| Neural Stem Cells | 1 | 2011 | 69 | 0.080 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2015 | 1145 | 0.080 |
Why?
|
| Medical Oncology | 1 | 2014 | 408 | 0.080 |
Why?
|
| Middle Aged | 8 | 2017 | 28208 | 0.080 |
Why?
|
| Brain Tissue Transplantation | 1 | 1990 | 5 | 0.080 |
Why?
|
| Risk Assessment | 2 | 2007 | 2480 | 0.080 |
Why?
|
| Antigens, Ly | 1 | 1990 | 37 | 0.080 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1990 | 96 | 0.080 |
Why?
|
| Lymphocyte Depletion | 1 | 1990 | 101 | 0.080 |
Why?
|
| Prognosis | 2 | 2007 | 3990 | 0.080 |
Why?
|
| Cognition Disorders | 1 | 2011 | 244 | 0.070 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2010 | 294 | 0.070 |
Why?
|
| Students, Medical | 1 | 2014 | 455 | 0.070 |
Why?
|
| Female | 13 | 2017 | 49872 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2009 | 2605 | 0.070 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1990 | 290 | 0.070 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2007 | 178 | 0.060 |
Why?
|
| Nerve Tissue | 1 | 1987 | 8 | 0.060 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2007 | 170 | 0.060 |
Why?
|
| Histocompatibility | 1 | 1987 | 66 | 0.060 |
Why?
|
| Lung Neoplasms | 2 | 2015 | 2386 | 0.060 |
Why?
|
| Epidermal Growth Factor | 1 | 2006 | 116 | 0.060 |
Why?
|
| Gene Amplification | 1 | 2006 | 142 | 0.060 |
Why?
|
| Cognition | 1 | 2011 | 635 | 0.060 |
Why?
|
| Drug Delivery Systems | 1 | 2007 | 198 | 0.060 |
Why?
|
| Multigene Family | 1 | 2006 | 213 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2007 | 517 | 0.060 |
Why?
|
| Expert Testimony | 1 | 2005 | 34 | 0.060 |
Why?
|
| Camptothecin | 2 | 2009 | 202 | 0.050 |
Why?
|
| Radiosurgery | 1 | 2007 | 316 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2013 | 3639 | 0.050 |
Why?
|
| United States | 3 | 2017 | 7764 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2007 | 933 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 1827 | 0.050 |
Why?
|
| Protein Binding | 1 | 2006 | 1560 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2005 | 655 | 0.050 |
Why?
|
| Survival Rate | 3 | 2011 | 1971 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 2773 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2017 | 883 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 3 | 1990 | 1124 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2006 | 1346 | 0.040 |
Why?
|
| Fatigue | 1 | 2021 | 185 | 0.040 |
Why?
|
| Models, Biological | 1 | 2006 | 1809 | 0.040 |
Why?
|
| Adult | 7 | 2015 | 28578 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2010 | 403 | 0.040 |
Why?
|
| Aged | 6 | 2017 | 20848 | 0.040 |
Why?
|
| Cerebral Ventricles | 2 | 1990 | 76 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2021 | 4664 | 0.040 |
Why?
|
| Mice, Inbred CBA | 2 | 1987 | 52 | 0.030 |
Why?
|
| Functional Laterality | 1 | 2017 | 208 | 0.030 |
Why?
|
| Brain | 1 | 2006 | 2480 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2017 | 599 | 0.030 |
Why?
|
| Skin Transplantation | 2 | 1987 | 193 | 0.030 |
Why?
|
| Infusions, Intravenous | 2 | 2010 | 420 | 0.030 |
Why?
|
| Isaacs Syndrome | 1 | 2015 | 2 | 0.030 |
Why?
|
| Young Adult | 3 | 2014 | 7026 | 0.030 |
Why?
|
| Syringomyelia | 1 | 2015 | 17 | 0.030 |
Why?
|
| Neoplasms | 1 | 2010 | 3242 | 0.030 |
Why?
|
| Mutation | 1 | 2006 | 4374 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 900 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 1008 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 640 | 0.030 |
Why?
|
| Gene Rearrangement | 1 | 2015 | 179 | 0.030 |
Why?
|
| Potassium Channels, Voltage-Gated | 1 | 2015 | 127 | 0.030 |
Why?
|
| Canada | 1 | 2014 | 214 | 0.030 |
Why?
|
| Drug Administration Schedule | 2 | 2009 | 857 | 0.030 |
Why?
|
| Comorbidity | 1 | 2017 | 1011 | 0.030 |
Why?
|
| Personnel Selection | 1 | 2014 | 64 | 0.030 |
Why?
|
| Quality of Life | 1 | 2021 | 1816 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1999 | 1087 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 1 | 1999 | 1087 | 0.020 |
Why?
|
| Registries | 1 | 2017 | 985 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 3106 | 0.020 |
Why?
|
| H-2 Antigens | 1 | 1990 | 57 | 0.020 |
Why?
|
| Thymectomy | 1 | 1990 | 32 | 0.020 |
Why?
|
| Mice | 3 | 1990 | 12537 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2010 | 270 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 1990 | 162 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 1990 | 297 | 0.020 |
Why?
|
| Curriculum | 1 | 2014 | 615 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2011 | 549 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2010 | 506 | 0.020 |
Why?
|
| Time Factors | 1 | 2017 | 5561 | 0.020 |
Why?
|
| Macrophage-1 Antigen | 1 | 1987 | 18 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 1987 | 104 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 1990 | 1023 | 0.020 |
Why?
|
| Necrosis | 1 | 1987 | 210 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1987 | 173 | 0.020 |
Why?
|
| Chicago | 1 | 2010 | 1505 | 0.010 |
Why?
|
| Internship and Residency | 1 | 2014 | 1134 | 0.010 |
Why?
|
| Animals | 3 | 1990 | 28889 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 3904 | 0.010 |
Why?
|
| Inflammation | 1 | 1987 | 1063 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 1987 | 1310 | 0.010 |
Why?
|
| Blood Cell Count | 1 | 1999 | 70 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 1999 | 119 | 0.010 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 1999 | 158 | 0.010 |
Why?
|
| Anticonvulsants | 1 | 1999 | 133 | 0.010 |
Why?
|
| Logistic Models | 1 | 1999 | 1267 | 0.010 |
Why?
|